Pre-emptive Local Anaesthesia in Gynecological Laparoscopy

This study has been completed.
Information provided by (Responsible Party):
Helse Stavanger HF Identifier:
First received: August 24, 2012
Last updated: November 20, 2014
Last verified: November 2014
Pre-emptive local anaesthetics are widely used in laparoscopic surgery, but there is no really consistent evidence that it is useful. Studies in the literature have shown contradicting results. At our hospital we are currently using pre-emptive local anaesthetics in the trocar areas, but as the literature does not give a clear and clinically relevant answer, we need to find out more. This study aims to see if pre-emptive local anaesthetics are useful in the setting of our day-case, laparoscopic surgery.

Condition Intervention Phase
Pain, Postoperative
Drug: Bupivacaine 5mg/ml
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Official Title: Pre-emptive Local Anaesthesia in Gynecological Laparoscopy

Resource links provided by NLM:

Further study details as provided by Helse Stavanger HF:

Primary Outcome Measures:
  • Postoperative movement-evoked pain [ Time Frame: 5 hours postoperative ] [ Designated as safety issue: No ]
    The primary outcome of the study will be movement-evoked pain (MEP) 5 hours after surgery, as half-life of bupivacaine is 4-6 hours. Movement-evoked pain is the most important outcome measure, because the goal is to get the patient back to normal, daily activities as soon as possible.

Secondary Outcome Measures:
  • Pain at rest [ Time Frame: 2 and 5 hours postoperative ] [ Designated as safety issue: No ]
    Secondary outcome measures will be pain at rest at 2 and 5 hours postoperative.

  • Rescue analgetics [ Time Frame: 5 hours postoperative ] [ Designated as safety issue: No ]
    Use of rescue analgesics postoperative.

Enrollment: 24
Study Start Date: February 2013
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: bupivacaine
Injection of 5 ml bupivacaine, 5mg/ml in each port site.
Drug: Bupivacaine 5mg/ml
5 ml in trocar area
Other Name: Marcain
Placebo Comparator: Placebo
Injection of 5 ml saline in each port site.

  Show Detailed Description


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Women ≥18 years of age
  • Planned day-case laparoscopic surgery
  • Signed Written Informed Consent

Exclusion Criteria:

  • ASA score 3-6
  • Chronic pain/ Regular use of analgesics
  • Inability to understand Norwegian language
  • Drug or alcohol abuse
  • Inability to understand or sign the Written Informed Consent form
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01677143

Stavanger University Hospital
Stavanger, Norway, 4068
Sponsors and Collaborators
Helse Stavanger HF
Principal Investigator: Caroline Ravndal, MD Helse Stavanger HF
  More Information

No publications provided

Responsible Party: Helse Stavanger HF Identifier: NCT01677143     History of Changes
Other Study ID Numbers: SUS2012CMR01, 2012-002356-16
Study First Received: August 24, 2012
Last Updated: November 20, 2014
Health Authority: Norway: Norwegian Medicines Agency
Norway:National Committee for Medical and Health Research Ethics

Keywords provided by Helse Stavanger HF:
Local anesthetic
Preemptive analgesia
Postoperative pain
Gynecological surgery
Day-case surgery

Additional relevant MeSH terms:
Pain, Postoperative
Pathologic Processes
Postoperative Complications
Signs and Symptoms
Anesthetics, Local
Central Nervous System Agents
Central Nervous System Depressants
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 25, 2015